Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1189-1196

  Zhang, Wei ^a   Chen, Hui ^b   Liu, Dian Lei ^b,c   Li, Hong ^d   Luo, Jiang ^b   Zhang, Jian Hong ^b   Li, Ye ^c   Chen, Kang Jie ^a   Tong, Hong Fei ^b   Lin, Sheng Zhang ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Second Hospital of Wenzhou   (China)

^c Hangzhou Hospital of Traditional Chinese Medicine   (China)

^d Wenzhou Vocational College of Science and Technology   (China)

Author keywords

Drug resistance; Emodin; NF B; Pancreatic cancer; Survival signaling

Indexed keywords

CASPASE 3; CASPASE 9; EMODIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EMODIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; NF-KAPPA B; P-GLYCOPROTEIN; PROTEIN BINDING; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84874601706     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1839     Document Type: Article

References (35)

1. Reske SN: PET and PET-CT of malignant tumors of the exocrine pancreas. Radiologe 49:131-136, 2009.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010.
3. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363:1049-1057, 2004.
4. Tempero MA, Behrman S, Ben-Josef E, et al: National Comprehensive Cancer Network. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 3:598-626, 2005.
5. Bredel M: Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161-204, 2001.
6. El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35:167-174, 2009.
7. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413, 1997.
8. Shuangsuo D, Zhengguo Z, Yunru C, Xin Z, Baofeng W, Lichao Y and Yan'an C: Inhibition of the replication of hepatitis B virus in vitro by emodin. Med Sci Monit 12: BR302-306, 2006.
9. Semple SJ, Pyke SM, Reynolds GD and Flower RL: In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral Res 49:169-178, 2001.
10. Li HL, Chen HL, Li H, et al: Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 116:41-47, 2005.
11. Chen RF, Shen YC, Huang HS, et al: Evaluation of the anti-inflammatory and cytotoxic effects of anthraquinones and anthracenes derivatives in human leucocytes. J Pharm Pharmacol 56:915-919, 2004.
12. Lin SZ, Chen KJ, Tong HF, Jing H, Li H and Zheng SS: Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats. Clin Exp Pharmacol Physiol 37:790-794, 2010.
13. Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS and Yi J: Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7:468-475, 2008.
14. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM and Lin YW: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79:655-664, 2010.
15. Huang Q, Lu G, Shen HM, Chung MC and Ong CN: Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27:609-630, 2007.
16. Gui M, Zhang YF, Xiao ZY, et al: Inhibitory effect of emodin on tissue inhibitor of metalloproteinases-1 (TIMP-1) expression in rat hepatic stellate cells. Dig Dis Sci 52:200-207, 2007.
17. Li J, Liu P, Mao H, Wang A and Zhang X: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21:1605-1610, 2007.
18. Chen H, Wei W, Guo Y, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25:1253-1261, 2011.
19. Lin SY, Lai WW, Ho CC, et al: Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. Anticancer Res 29:327-335, 2009.
20. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241-246, 2001.
21. Weldon CB, Burow ME, Rolfe KW, et al: NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 130:143-150, 2001.
22. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5:412-417, 2009.
23. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309, 2005.
24. Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH: Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med Oncol 29:534-538, 2010.
25. Banerjee S, Wang Z, Kong D and Sarkar FH: 3, 3'-Diindolyl-methane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69:5592-5600, 2009.
26. Bentires-Alj M, Barbu V, Fillet M, et al: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90-97, 2003.
27. König J, Hartel M, Nies AT, et al: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115:359-367, 2005.
28. Hao Z, Li X, Qiao T, Du R, Hong L and Fan D: CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol Ther 5:261-266, 2005.
29. Chen C, Shen HL, Yang J, Chen QY and Xu WL: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 137:9-17, 2011.
30. Leonessa F and Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73, 2003.
31. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845-1853, 1997.
32. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM and Ryan BM: Survivin: a promising tumor biomarker. Cancer Lett 249:49-60, 2007.
33. Cohen C, Lohmann CM, Cotsonis G, Lawson D and Santoianni R: Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 16:574-583, 2003.
34. Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5:65-72, 2002.
35. Connolly K, Mitter R, Muir M, Jodrell D and Guichard S: Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 64:307-316, 2009.